Previous 10 | Next 10 |
IRVING, Texas, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that three abstracts highlighting clinical and nonclinical data for bardoxolone methyl (bardoxolone) will be presented at the American Soc...
Reata Pharmaceuticals (NASDAQ: RETA ) has reacquired development and commercialization rights to its Nrf2 activator product platform from licensee AbbVie (NYSE: ABBV ). Specifically, it owns exclusive global rights bardoxolone methyl, omaveloxolone and all other next-generation Nrf2 activa...
IRVING, Texas, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the reacquisition of development, manufacturing and commercialization rights concerning its proprietary Nrf2 activator product platform or...
Insider buying more than doubled last week with insiders purchasing $125.79 million of stock last week compared to $57.61 million in the week prior. Selling, on the other hand, declined with insiders selling $508.49 million of stock last week compared to $683.67 million in the week prior. S...
Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Outperform rating and $146 (45% upside) price target at William Blair. More news on: Alexion Pharmaceuticals, Inc., Change Healthcare Inc., Denali Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Reata Pharmaceuticals, Inc (RETA) Q2 2019 Earnings Conference Call August 8, 2019 8:00 AM ET Company Participants Vinny Jindal – Vice President of Strategy Warren Huff – Chief Executive Officer Colin Meyer – Chief Medical Officer Jason Wilson – Chief...
Reata Pharmaceuticals (NASDAQ: RETA ): Q2 GAAP EPS of -$1.14 misses by $0.02 . More news on: Reata Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
IRVING, Texas, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2019, and provided an update on the Company’s business and product developm...
IRVING, Texas, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs on Thursday, August 8, 2019, at...
CNS Pharmaceuticals ( CNSP ) has filed a preliminary prospectus for a 2.125M-share IPO at $4 -5 per share, valuing the offering at $9.6M from the midpoint. More news on: CNS Pharmaceuticals, Reata Pharmaceuticals, Inc., Healthcare stocks news, IPO News, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023